Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 10/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 10/20 | 1.00 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16740905 | 0.78 | PDE3B (0.64) | PDE3BPDE3AKDM4EALDH1A1HPGD | |
| SCHEMBL19147135 | 0.76 | PDE3B (0.61) | PDE3BPDE3AMAOAKDM4EALDH1A1 | |
| SCHEMBL16740903 | 0.76 | PDE3B (0.65) | PDE3BPDE3APDE10AKDM4EALDH1A1 | |
| SCHEMBL16740923 | 0.75 | PDE3B (0.74) | PDE3BPDE3APDE10A | |
| Hydrochloric Acid SCHEMBL18128185 | 0.73 | PDE3B (0.72) | PDE3BPDE3APDE10A | |
| SCHEMBL16747721 | 0.73 | PDE3B (0.57) | PDE3BPDE3AKDM4EALDH1A1HPGD | |
| SCHEMBL16740918 | 0.69 | PDE3B (0.53) | PDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL16740910 | 0.69 | PDE3B (0.66) | PDE3BPDE3APDE10A | |
| SCHEMBL7440342 | 0.69 | PDE3B (0.73) | PDE3BPDE3APDE10AKDM4EALDH1A1 | |
| SCHEMBL1470937 | 0.68 | PARP15 (0.52) | PDE3BPDE3AKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738630-B2 | Inhibitors of lysine methyl transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738630-B2 | Inhibitors of lysine methyl transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738630-B2 | Inhibitors of lysine methyl transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160297806-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297806-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297806-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2016-10-13 | — | — | US | disclosed |
| WO-2015077193-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015077193-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297806-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | EZH2, DOT1L, EHMT1 | PDE3B 3943/4885PDE3A 3977/4885PDE10A 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.